Insights & Resources – COD Research

Medical Affairs

CT Quality Assurance

Clinical Services

Biometrics

Transforming Complexity into Success: A Large-Scale Global Phase III Biosimilar Dermatology Trial

Strategic Planning for Patient Recruitment

Pulmonary Disease Introduction: Prevalence, Causes, Prevention & Treatment

EMA
FDA
MHRA

Human medicines European public assessment report (EPAR): Absimky, ustekinumab, Date of authorisation: 12/12/2024, Revision: 1, Status: Authorised
Source: EMA Published on 2025-05-28
Human medicines European public assessment report (EPAR): NovoRapid, insulin aspart, Date of authorisation: 07/09/1999, Revision: 34, Status: Authorised
Source: EMA Published on 2025-05-28
Human medicines European public assessment report (EPAR): Riximyo, rituximab, Date of authorisation: 15/06/2017, Revision: 16, Status: Authorised
Source: EMA Published on 2025-05-28
Human medicines European public assessment report (EPAR): Efficib, sitagliptin,metformin, Date of authorisation: 15/07/2008, Revision: 36, Status: Authorised
Source: EMA Published on 2025-05-28
Human medicines European public assessment report (EPAR): Truxima, rituximab, Date of authorisation: 17/02/2017, Revision: 24, Status: Authorised
Source: EMA Published on 2025-05-28
Human medicines European public assessment report (EPAR): Xolair, omalizumab, Date of authorisation: 25/10/2005, Revision: 52, Status: Authorised
Source: EMA Published on 2025-05-28

Read More